The gap between optimal management of advanced NSCLC and current clinical practice is widening as many oncologists remain unaware of new and emerging clinical evidence and how best to apply advances to their clinical practice. Oncologists have an opportunity to prolong life and improve the quality of life in selected patients with advanced NSCLC by more thoroughly defining molecular subsets of advanced NSCLC and more fully integrating the use of targeted therapies into treatment regimens. Assessing and incorporating new data from the ASCO meeting will assist oncologists in individualizing therapy for their patients with NSCLC and achieving these goals.
Oncologists and other health care professionals involved in the care of patients with NSCLC.
- Review the proposed guidelines for testing of biomarkers in NSCLC.
- Differentiate evolving approaches surrounding the use of prognostic and predictive biomarkers in patients with NSCLC.
- Summarize recent advances in the use of targeted medical therapy in patients with NSCLC.
- Assess new clinical trial data surrounding targeted therapies for NSCLC.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in each activity.
Jeffrey Crawford, MD (Moderator)
George Barth Geller Professor for Research in Cancer
Chief of Medical Oncology
Department of Medicine
Duke University Medical Center
Philip D. Bonomi, MD, MS
Alice Pirie‐Wirtz Professor of Medicine
Director, Division of Hematology‐Oncology
Rush University Medical Center
Shirish Gadgeel, MD
Department of Oncology
Karmanos Cancer Institute
Wayne State University
The “Conflict of Interest Disclosure Policies” of Albert Einstein College of Medicine of Yeshiva University require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.
Dr. Crawford discloses he is a consultant with and receives research funding from Aggenix, Amgen, and GTX; and is on DSMBs of Facet Biotech (Abbott), Merrimack Pharma, and Roche.
Dr. Bonomi discloses he received research funding from Aggenix, Cycladel, Lilly, and Pfizer; and is on DSMBs for Infinity and Pfizer.
Dr. Gadgeel discloses he is on the speakers' bureau for Astellas, Genentech, and Pfizer.
Disclosure of Unlabeled Use
The Albert Einstein College of Medicine of Yeshiva University (Einstein) also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
©2012, Albert Einstein College of Medicine of Yeshiva University and MCM Education. All rights reserved. This publication is designed to provide the health care professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. None of the contents may be reproduced in any form without prior written permission from Albert Einstein College of Medicine and the publisher. The opinions expressed in this video roundtable are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine, Boehringer Ingelheim Pharmaceuticals, Inc., or Astellas Pharma Global Development, Inc. Any medications or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks or without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.
This program is sponsored by Albert Einstein College of Medicine of Yeshiva University.
This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Astellas Pharma Global Development, Inc.
For full program information, please click on “BEGIN” button and follow the next click-through to reach this program site. Once you get to the “CMEcorner.com” site description page, you will review program information, program content, take the test, complete evaluation, and receive credit with a post-test score of at least 60%.
If you have any questions relating to the accreditation of this activity, please contact:
Center for Continuing Medical Education
Bronx, NY 10467
If you have any questions relating to other issues of this activity, please contact myCME.Support@haymarketmedical.com.
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.